期刊文献+

抗肿瘤药Pomalidomide的合成 被引量:8

Synthesis of Antitumor Agent Pomalidomide
下载PDF
导出
摘要 N-(叔丁氧羰基)-L-谷氨酰胺(2)经闭环、脱保护制得3-氨基-2,6-哌啶二酮三氟乙酸盐(4)。另用3-硝基邻苯二甲酸(5)脱水制得3-硝基邻苯二甲酸酐(6)。4和6经缩合、铁粉/浓盐酸还原制得免疫调节剂类抗肿瘤药3-氨基-N-(2,6-二氧代-3-哌啶基)-邻苯二甲酰亚胺,以5计总收率约35%。 Pomalidomide, an immunomodulator, was synthesized from 3-nitrophthalic acid (5) by dehydration to give 3-nitrophthalic anhydride (6), which was subjected to the reaction with 3-aminopiperidine-2,6-dione trifluoroacetate (4) to afford 3-nitro-N-(2,6-dioxopiperidin-3-yl)-phthalimide (7) followed by reduction with Fe/HCl in an overall yield of about 35 % ( based on compound 5). Compound 4 was prepared from N-Boc-L-glutamine by cyclization and deprotection.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2009年第10期721-723,共3页 Chinese Journal of Pharmaceuticals
关键词 POMALIDOMIDE 免疫调节剂 抗肿瘤药 合成 pomalidomide immunomodulator antitumor agent synthesis
  • 相关文献

参考文献10

  • 1Tricot S, Berthon C, Venon M, et al. Thalidomide in multiple myeloma in the elderly [J]. Aging Health, 2009, 5 (1) : 1-17.
  • 2Galustian C, Meyer B, Labarthe M, et al. The anticancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells [J]. Cancer Immunology Immunotherapy, 2009, 58 (7) : 1033-1045.
  • 3Zhu D, Corral GL, Fleming YW, et al. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation [J]. Cancer Immunology Immunotherapy, 2008, 57 (12) : 1849-1859.
  • 4Muller GW, Saindane MT, Chuansheng GE, et al. Processes for the preparation of 4-amino-2- (2,6-dioxopiperidin-3- yl) isoindoline-l,3-dione: EP, 20060786385 [P]. 2006-06-29.
  • 5袁修华,郭海泉,邱雪鹏,康传清,刘旭东,高连勋.一步法合成沙利度胺及其重要的衍生物[J].高等学校化学学报,2005,26(8):1477-1479. 被引量:5
  • 6Zhu XX, Giordano T, Yu QS, et al. Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-α inhibitory activity [J]. J Med Chem, 2003, 46 (24) : 5222-5229.
  • 7Perino S, Contino-Pepin C, Satchi-Fainaro R, et al. Inhibition of angiogenesis by THAM-derived cotelomers endowed with thalidomide moieties [J]. Bioorg Med Chem Lett, 2004, 14 (2) : 421-425.
  • 8陈志敏,左霞,吴谊群,陈耐生.3-硝基邻苯二甲腈的合成[J].合成化学,2004,12(2):167-169. 被引量:11
  • 9Stewart SG, Spagnolo D, Polomska ME, et al. Synthesis and TNF expression inhibitory properties of new thalidomide analogues derived via Heck cross coupling [J]. Bioorg Med Chem Lett, 2007, 17 (21) : 5819-5824.
  • 10Varala R, Adapa SR. A practical and efficient synthesis of thalidomide via Na/liquid NH3 methodologyl [J].Org Process Res Dev, 2005, 9 (6) : 853-856.

二级参考文献21

  • 1Aihara Shin,Itoh Hisato,Oguchi,Takahisa,et al.Amorphous Phthalocyanine Compound or Mixture of Amorphous Phthalocyanine Compounds, and Method for Preparing Same[P]. US 5 358 833,1992.
  • 2Ozer Bekaroglu.Synthesis of Phthalocyanines and Related Compounds[J].Journal of Porphyrins and Phthalocyanines,2000,4(5):465-473.
  • 3Sasaki Nobuaki.Production of Alkoxyphthalonitrile[P].JP 6 234 721,1994.
  • 4Oguchi Takahisa,Sugimoto Kenichi, Aihara Sjin,et al.Method for Preparing Alkoxyphthalocyanine[P].US 5 334 714,1994.
  • 5Gregory Peter.Industrial Applications of Phthalocyanines[J].Journal of Porphyrins and Phthalocyanines,2000,4(4):432-437.
  • 6H盖而曼 A 勃拉特.有机合成(第一集)[M].北京:科学出版社,1965.328-331.
  • 7Stuart W,Oliver,Thomas D Smith. Synthesis and Characterization of 2,9,16,23-Tetra(3-pyridyloxy)-phthalocyanine in the form of Its Zinc(Ⅱ) Chelate[J].Heterocycles,1984,22(9):2047-2052.
  • 8Stirling S, M.. Strauss S,. J. Am. Pharm. Assoc. [J]. 1997. NS37(3): 306-313.
  • 9Walkenhorst A,. Wien. Klin, Wochschr. [J]. 1957. 69:334-339.
  • 10LenzW,. Lancet[J]. 1962. 1: 45-46.

共引文献13

同被引文献58

  • 1袁修华,郭海泉,邱雪鹏,康传清,刘旭东,高连勋.一步法合成沙利度胺及其重要的衍生物[J].高等学校化学学报,2005,26(8):1477-1479. 被引量:5
  • 2宋丽洁,封宇飞,傅得兴,胡欣,王唯红.新型免疫调节药来那度胺的药理及临床研究进展[J].中国新药杂志,2006,15(21):1889-1892. 被引量:14
  • 3张丽,叶志义.整合素与肿瘤的转移与血管生成[J].现代生物医学进展,2007,7(2):290-292. 被引量:2
  • 4Kale V, List AF. Immunomodulatory drugs (IMiDs^TM) : a new treatment option for myelodysplastic syndromes [J]. Curr Pharm Biotechnol, 2006, 7 (5) : 339-342.
  • 5Raghavendracharyulu PV, Veerender M, Amarendhar M. An improved process for the preparation of lenalidomide: IN, 2006CH00047 [P]. (CA2008, 149: 402200).
  • 6Zhu XX, Giordano T, Yu QS, et al. Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-α inhibitory activity [J]. J Med Chem, 2003, 46 (24) : 5222-5229.
  • 7Fox D J, Reckless J, Warren SG, et al. Design, synthesis and preliminary pharmacological evaluation of N-acyl-3- aminoglutarimides as broad-spectrum chemokine inhibitors in vitro and anti-inflammatory agents in vivo [J]. J Med Chem, 2002, 45 (2) : 360-370.
  • 8De Lucca GV, Kim UT, Johnson C, et al. Discovery and structure-activity relationship of N- (ureidoalkyl) -benzylpiperidines as potent small molecule CC chemokine receptor- 3 (CCR3) antagonists [J]. J Med Chem, 2002, 45 (17) : 3794-3804.
  • 9Muuler GW, Stirling DI, Chen RSC, et al. Substiuted 2-(2,6-dioxopiperidin-3-yl) phthalimides and methode of reducing TNF-α levels: WO, 9803502 [P]. 1998-01-29.
  • 10尤启冬.药物化学[M].北京:化学工业出版社,2003,527-529.

引证文献8

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部